- Conditions
- Adamantinomatous Craniopharyngioma
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
- Interventions
- Binimetinib Oral Tablet [Mektovi]
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 2 more
- Conditions
- Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more